FROM:
J Gastroenterol. 2004 (Sep); 39 (9): 873878 ~ FULL TEXT
Kyosuke Kaji, Satoshi Yoshida, Nobuo Nagata, Tatsuya Yamashita,
Eishiro Mizukoshi, Masao Honda, Yasuhiko Kojima, and Shuichi Kaneko
Department of Gastroenterology,
Kanazawa University Hospital,
Ishikawa, Japan
Why was this study done?
To determine the effects of a traditional Japanese (Kempo) formula on aspects of the immune system in patients with chronic hepatitis. The formula, called EH0202, includes pumpkin seeds (Cucurbita moschata), plantain seeds (Plantago asiatica), Japanese honeysuckle (Lonicera japonica), and safflower (Carthamus tinctorius).
What This Study Found
After three months of EH0202 administration, there were significant reductions in the measurement of hepatitis C virus (titers) in the blood of participants as well as significant improvements in symptoms (malaise).
|
BACKGROUND: In this study, we examined the effect of EH0202, a mixture of four herbal extracts that are known to induce interferons, on hepatitis C virus (HCV)-RNA levels in patients with chronic hepatitis C.
METHODS: This was an open-label uncontrolled study. The study subjects ingested food containing EH0202 daily for 3 months, which was equivalent to 1 g of desiccated herbs daily. Clinical symptoms, hematology and biochemical examinations, urine, and HCV-RNA levels were examined before, during (1 month), and after the EH0202 treatment (3 months).
RESULTS: Among the 35 patients who successfully completed the study, there were improvements in malaise (seen in 6 patients before and in 2 after EH0202 treatment), bloating sensation in the abdomen (seen in 2 before and in none after treatment), and nausea and vomiting (seen in 2 before and in 1 after treatment). There were no changes in hematology or biochemical examination parameters. There was a statistically significant decrease in HCV-RNA levels in patients with high viral titers after 3 months of EH0202 administration. No serious adverse events were observed with the EH0202 treatment.
CONCLUSIONS: These findings suggest that EH0202 may be safe and useful in the treatment of patients with chronic hepatitis C. Further studies are, however, needed to obtain a definitive conclusion.
From the FULL TEXT Article:
Introduction
In recent years, the number of people who use health
foods has been increasing, reflecting an increase in
public awareness of diet and fitness for improving
health. However, there have been few clinical studies
that evaluated the safety and efficacy of these healthfood
products.
EH0202 is a health-food additive that was developed
by Yamanouchi Pharmaceutical Co., Ltd. (Tokyo,
Japan). It is a mixture of four herbal extracts (see below)
that are known to stimulate macrophage activity.
Dr. Yasuhiko Kojima, [1] who was the first to describe
interferon (IFN), in 1970, and who is one of the foremost
experts in this field, together with his fellow researchers,
has screened some 200 herbs commonly used
as traditional Kampo (Chinese medicine) formulations
in Japan. Based on their screening, four herbs were
finally selected that were shown to be IFN inducers [2] and
could be used as food additives. They were:
pumpkin seeds (Cucurbita moschata),
plantain seeds (Plantago asiatica),
Japanese honeysuckle (Lonicera japonica),
and safflower (Carthamus tinctorius).
EH0202 is a mixture of these four extracts.
It has been shown that EH0202 administration
decreases the incidence of viral pneumonia and the
mortality rate in pigs with porcine reproductive and
respiratory syndrome. [3] In addition, in postmenopausal
women, oral EH0202 administration for 6 months improved
subjective menopausal symptoms and increased
granulocyte-macrophage colony-stimulating factor
(GM-CSF) levels, while decreasing follicle-stimulating
hormone (FSH) levels in blood. Thus, it appears that
EH0202 acts to stimulate immunological systems and
may improve endocrine dysfunction. [4]
IFNs have been used to treat patients with chronic
hepatitis C, and, because EH0202 has been shown to
stimulate macrophages and increase IFN levels in experimental
animals, we examined the effect of EH0202
on hepatitis C virus (HCV)-RNA levels, clinical symptoms,
and hematological and biochemical parameters in
patients with chronic hepatitis C, in an open-label
uncontrolled study.
Methods
Patients
The subjects included in the study were 50 patients with
chronic hepatitis C (26 men and 24 women; 2880 years
old; mean ± SD, 59.0 ± 10.6 years old), who visited
the Kanazawa University Hospital from February to
November 2002. This study was carried out as an open-label
study. Hepatitis C was diagnosed by the referring
physicians, and the patients included in the study were
those who agreed, in writing, to participate in the study.
HCV serotypes were: group 1 (40 patients), group 2 (9
patients), and unknown (1 patient). Twenty-four patients
had a history of receiving IFN therapy in the past.
After completion of the study, 15 of the 50 patients
were excluded from the efficacy analysis for one of the
following reasons: inappropriate dosage and/or administration
(4 patients), data missing (4 patients), IFN
had been administered during the 6 months prior to
the commencement of administration of EH0202 (3 patients),
premature discontinuation of EH0202 administration
(2 patients), administration of IFN commenced
during the EH0202 dosing period (1 patient), and a
complication (hepatic tumor) was observed prior to
administration (1 patient).
Thus, efficacy was examined
based on the data of 35 evaluable subjects (17 men and
18 women; 2880 years old; mean ± SD, 60.5 ± 10.4
years). The number of patients classified based on the
HCV serotype was 27 patients for group 1, 7 patients for
group 2, and 1 patient, unclassified. Of the 35 evaluable
patients, 15 patients had a previous history of receiving
IFN therapy. The 15 patients excluded from the efficacy
evaluation of EH0202, who nonetheless, took EH0202,
were included in the safety analysis, together with the 35
evaluable patients.
During the EH0202 treatment period, concomitant
medications for the liver conditions were used in 22
patients. Thirteen patients had received ursodeoxycholic
acid prior to and during the study. During
EH0202 treatment, 5 patients started to take ursodeoxycholic
acid for the first time. A glycyrrhizin
preparation was used in conjunction with ursodeoxycholic
acid in 2 patients, and in conjunction with
Kantec (malotilate; Daiichi Pharmaceutical, Tokyo,
Japan) and Proheparum S (liver hydrolysate; Kaken
Pharmaceutical, Tokyo, Japan) tablets in 1 patient.
Taurine powder was used in conjunction with ursodeoxycholic
acid in 1 patient. Aminoleban (a branchchained
amino acids; Otsuka Pharmaceutical, Tokyo,
Japan), Shosaiko-to (a bupleurum root-based formula;
Tsumura, Tokyo, Japan), and Proheparum tablets were
used as single agents in 1 patient each.
Test product
In this study, we used InterPunch (Sanwell, Tokyo,
Japan), a commercially available form of EH0202, as
the test product. EH0202 is a mixture of four herbal
extracts: Cucurbita moschata (seeds), Plantago asiatica
(mature seeds), Lonicera japonica (flowers and flower
buds), and Carthamus tinctorius (dried tubular flowers).
These herbs were dried and weighed and then added to
water equal to ten times the total weight of the dried
herbs. The mixture was heated for 30 min at 95 ± 5°C in
order to prepare an extract. The extract was strained
and condensed. Inactive ingredients and flavors, such as
lactulose, maltitol, lactose, and starch, were added to
the extract. The mixture was then formed into fine granules.
Finally, the granules and Bifidobacterium longum
were combined to prepare the product. Two packets
of InterPunch (1.5 g X 2 packets), which is the daily
dosage, contain the equivalent of 1g of the dried herbs
listed above.
Test parameters
Six clinical symptoms, namely, nausea and vomiting,
abdominal pain, a bloating sensation in the abdomen,
hematemesis and hematochezia, pruritus, and malaise,
were examined. The clinical symptoms were examined
and recorded by physicians when each patient visited
the hospital. The parameters in hematological examinations
were: white blood cell count, red blood cell count,
hemoglobin, hematocrit, platelet count, and differential
white blood cell count. The parameters in the biochemical
examinations were: aspartate aminotransferase
(AST), alanine aminotransferase (ALT), alkaline phosphatase,
γ-guanosine triphosphate (GTP), Zincsulfate
Turbidity Test (ZTT), lactic dehydrogenase (LDH),
urea nitrogen, creatinine, Na, K, Cl, total bilirubin, total
protein, albumin, total cholesterol, and triglycerides.
Urinalysis parameters were protein, glucose, and occult
blood. HCV-RNA levels were quantified, using
AMPLICOR version 2.0 assay (Roche Diagnostics,
Tokyo, Japan). The HCV antibody titer was measured
using Lumipulse II Ortho HCV (Ortho-Clinical Diagnostics,
Tokyo, Japan); the standard upper limit is
850 KIU/ml in this assay. If the measurement was above
this value, HCV-RNA was remeasured following appropriate
dilution of the sample. These measurements
were performed prior to and 1 month and 3 months
following the commencement of administration of
EH0202.
Statistical analysis
Data from hematological and biochemical examinations,
HCV-RNA analyses, and the HCV antibody
assays were analyzed by means of Students t-test. The
efficacy of concomitant medications was analyzed by
means of the χ2 test.
Results
Clinical symptoms
Table 1
|
Malaise was observed in six patients prior to administration.
At 1 month of administration, improvement was
observed in four of the six patients (66.7%). Improvement
was also observed in the same four patients after 3
months of administration (Table 1). Two patients had a
bloating sensation in the abdomen, and improvement
was observed in one of the two patients (50%) after 1
month of administration, and in both patients (100%)
after 3 months of administration. Two patients had
nausea and vomiting, and improvement was observed
in one of the two patients (50%) after 3 months of
administration.
Blood and biochemical examinations, and urinalysis
Table 2
Table 3
|
No change was observed in any hematological parameters,
such as white blood cell (WBC) count, red blood
cell count, hemoglobin, hematocrit, and platelet count
(Table 2). Administration of EH0202 did not influence
WBC differentials (data not shown).
In biochemical examinations, ZTT was 17.5 ± 7.6 IU/l prior to administration, while it was
18.4 ± 7.8 IU/l after 3 months of administration. The increase
was significant (P < 0.05). Na was 141.5 ± 2.2mEq/l
prior to administration, while it was 142.7 ± 2.0mEq/l
after 1 month of administration. This increase was also
significant (P < 0.01). However, serum Na concentration
after 3 months of administration was similar to the
value prior to administration (141.1 ± 2.2 mEq/l). Parameters
that indicate the level of hepatic and/or renal
function did not change during the study (Table 3). No
change was observed in the hematological or biochemical
indices following the cessation of EH0202 administration.
No significant change was observed in urinalysis
findings.
HCV-RNA quantification and HCV antibody titer
Average HCV-RNA levels for the 35 patients were
734.4 ± 716.1 KIU/ml, 605.1 ± 471.1 KIU/ml, and 578.7 ± 437.9KIU/ml prior to and 1 month and 3 months
following the commencement of EH0202 administration,
respectively (means ± SD). Although HCV-RNA
levels tended to decrease with time, the decrease was
statistically insignificant.
Figure 1
|
Further analysis was conducted by classifying patients
into one of four groups, based on their baseline HCVRNA,
i.e., below 100KIU/ml, 100499KIU/ml, 500
849KIU/ml, and over 850 KIU/ml. As shown in Figure 1,
HCV-RNA levels had decreased significantly after 1
and 3 months of administration in patients in the over-
850-KIU/ml group (n = 12; P = 0.044 and P = 0.024,
respectively). HCV-RNA had also decreased significantly
after 3 months of administration in patients in
the 500- to 849-KIU/ml group (n = 9; P = 0.021). In
general, no significant change was observed in patients
with HCV-RNA levels below 500KIU/ml, except
for one patient who had a level of HCV-RNA of
1.4 KIU/ml before administration, with a level below
the detection limit after 1 month of EH0202 administration.
The level in this patient remained below the detection
limit both at 1 month and 3 months after the
cessation of the administration. We also tried to collect
data on viral RNA levels after the study, but it was
virtually impossible to collect useful data, because patients
were treated with various drugs and regimens,
including IFN.
A statistical analysis of the HCV antibody titer was
carried out. Complete sets of antibody data were available
only for 25 patients. The HCV antibody titer was
66.44 ± 7.78 HCV-Ab index, 67.17 ± 7.00 HCV-Ab
index, and 66.83 ± 8.23 HCV-Ab index prior to and at
1 month and 3 months of administration, respectively.
That is, no change was observed in the HCV antibody
titer following EH0202 treatment. Further analysis by
group, as specified above, did not show significant
change either.
No significant correlation between HCV-RNA and
AST/ALT was observed in patients whose HCV-RNA
decreased significantly. In addition, we performed the
χ2 test in order to analyze the difference, with respect
to changes in HCV-RNA, between patients using
concomitant drugs and patients not using concomitant
drugs. The difference, with respect to changes in HCVRNA,
between patients using ursodeoxycholic acid,
which was the most commonly used concomitant drug
in this study, and patients not using ursodeoxycholic
acid was also analyzed. In all cases, no significant difference
was observed. No particular trend was observed
between improvement in clinical signs/symptoms and
the amount of virus.
Adverse events
A 71-year-old female patient had mild diarrhea in the
first month of the dosing period, but the diarrhea
disappeared with continued use of EH0202. A 60-year-old male patient experienced a mild bloating
sensation in the abdomen during the third month of
the dosing period, which did not call for termination
of EH0202 treatment. No other adverse events were
observed.
Discussion
Currently there are 4 million patients with viral hepatitis
in Japan. In addition, it is thought that there are
more than 1 million carriers of HCV. [5] In the United
States, it is known that 4 million people have been infected
with HCV. [6] Thus, hepatitis is a major international
health problem which requires significant medical
attention.
The general strategies for the treatment of chronic
hepatitis C are to eradicate HCV and to suppress hepatitis.
IFNs are the mainstay in the treatment of hepatitis
C by eradicating HCV; however, complete responses
are not always obtained, and the treatment is not without
side effects. More recently, a combination of IFN
and ribavirin has been introduced as a better treatment
of chronic hepatitis C; however, a complete response
has yet to be seen, and this treatment is also associated
with side effects such as granulocytopenia, thrombocytopenia,
and flu-like symptoms.
The present study was an open-label, uncontrolled
study of the effect of EH0202 in patients with chronic
hepatitis C. In addition to the examination of clinical
symptoms, quantification of hematological indices,
biochemical examinations, and determination of HCVRNA
levels were made prior to and 1 month and 3
months after the commencement of EH0202 treatment.
The most notable finding was a significant decrease in
HCV-RNA levels, which was found in patients with
viral titers higher than 500KIU/ml. Namely, there was
a statistically significant decrease in HCV-RNA in the
500- to 849-KIU/ml group, at 3 months, and in the over-
850-KIU/ml group at 1 month and 3 months following
EH0202 commencement (P < 0.05). In addition, a few
patients showed improvement in certain clinical symptoms,
but this was not found in all subjects.
It has been reported that the coefficients of variation
of the version 2.0 AMPLICOR test range from 18% to
39%. [7] In our study, the amount of virus in patients with
a high viral load (over 850 KIU/ml) decreased to 65.7%
of the baseline value (on average, from 1447KIU/ml to
951KIU/ml) following the administration of EH0202,
which fell within the range of the reported variation. [7]
Thus, no definitive conclusion could be made from
this study, and further studies are needed to clarify this
question. It has been shown in animal studies that
EH0202 promotes the phagocytic activity of macrophages
(monocytes) in blood when it is administered to
dairy cattle. [8] It has also been reported that EH0202
promotes the phagocytic activity of peritoneal macrophages
and promotes IFN production in blood in mice
following oral administration. [9] These findings in experimental
animals suggest that EH0202 induces IFNs
within the body, which may lead to an increase in antiviral
activity.
Abnormally elevated levels of AST and ALT in
patients with chronic hepatitis C were not decreased
or influenced by EH0202 treatment, even in patients
whose HCV-RNA levels were significantly decreased.
Thus, there was no overt correlation between the
amount of viral load and the indices of hepatic dysfunction.
It has been reported that the prognosis of hepatic
diseases depends on decreases in AST and ALT. [10] In
contrast, it is not yet known if a decrease in viral load is
directly correlated with clinical improvement in patients
with hepatitis C. Nevertheless, the use of EH0202,
either concomitantly with, or without other medications,
may be effective in the treatment of hepatitis C,
because a complete response to IFN treatment is known
to depend critically on a decrease in the viral load. In
addition, because hepatitis C virus is implicated not
only in the inflammatory process in hepatitis but also in
the carcinogenic process leading to the development of
hepatoma, [11] it appears prudent to suppress the viral titer
as much and for as long as possible.
With respect to clinical symptoms, even though relatively
few patients experienced symptoms at the outset
of the study, the improvements were notable. At 3
months of EH0202 administration, improvements were
observed in four of the six patients who experienced
malaise, in two of the two patients who had a bloating
sensation in the abdomen, and in one of the two patients
who had nausea/vomiting. No patient experienced exacerbation
of the clinical symptoms that had been
observed prior to administration during or after
EH0202 treatment. These findings thus suggest that
EH0202 may also contribute to improvements in quality
of life (QOL), and if so, EH0202 may be a useful healthfood
additive with antiviral potency. However, further
studies are needed to definitively prove this point, because
the current study was an open-label uncontrolled
study, which does not permit such conclusions.
In this study, two adverse events, both minor, were
observed. One was mild diarrhea, which was observed
during the first month of the dosing period. The patient
recovered soon after, despite continuation of EH0202
administration, and it was therefore considered a transient
reaction. Because InterPunch used in this study
contains Bifidobacterium longum, the diarrhea may
have been caused by this bacterium. The other adverse
event was a mild bloating sensation in the abdomen,
which was observed in a 60-year-old male patient during
the third month of the dosing period, but it was mild and
did not necessitate stopping EH0202 treatment. No
other adverse event was observed in the 35 evaluable
patients, or in the other 15 patients who did not qualify
for evaluation of efficacy, but took EH0202 in the study.
These findings suggest that oral administration of
EH0202 daily for 3 months is not associated with any
serious adverse event; thus, it can be considered safe.
It is known that IFNs can be toxic in high doses, as
intensive IFN therapy greatly influences immunomodulation
and causes adverse drug reactions that occur in
the central nervous, endocrine, and/or digestive systems.
In contrast to direct IFN therapy, indirect stimulation
of IFN production in the body by various means
has not been shown to cause any adverse events. Thus,
the finding of no adverse events induced by EH0202
treatment is also consistent with the existing knowledge,
and oral EH0202 treatment can be considered safe.
Our findings in this study suggest that oral EH0202
treatment may decrease the viral load in patients with
chronic hepatitis C, as soon as 1 month after its administration
is begun. The effect of EH0202 appears to be
more dominant in patients with high viral titers than in
those with a low titer. In some patients, EH0202 may
also improve certain symptoms, such as malaise. That
oral EH0202 treatment is safe was also shown by the
lack of any serious adverse event associated with
the treatment, and by the finding that parameters in the
blood and biochemical examinations did not worsen.
While it is clear that many more studies are necessary to
clearly define the safety and the efficacy of EH0202, the
preliminary findings in our present study suggest that
EH0202 may be a useful health-food additive with antiviral
activity to be used in the treatment of chronic
hepatitis, such as hepatitis C, and it merits further
investigation.
References:
Kojima Y.
Sites of interferon production in rabbits induced by bacterial endotoxin.
Kitasato Arch of Exp Med 1970;43:3544.
Kojima Y. Kampo medicines and interferon inducers.
Kampo Medicine 1981;5:915.
Toriumi H, Ichikawa Y, Terao T, Yamagiwa K, Shimizu K,
Takeishi M, et al.
Clinical efficacy of the feed additive MACH on the incidence of respiratory diseases in piglets.
In: Proceedings of Guangzhou International Conference on the Advanced Traditional Chinese Veterinary Medicine 2000; 2000 Oct 1518;
Guangzhou, China. South China Agricultural University,
Guangzhou, China; 2000. p. 1936.
Ushiroyama T, Yoshida S, Tadaki K, Ikeda A, Ueki M.
A pilot study of a Kampo formula, EH0202, with intriguing results for menopausal symptoms.
J Altern Complement Med 2004;10:3979.
Satoh T.
Report on a meeting of professionals to discuss combating hepatitis.
Tokyo: Health Science Division, Ministers secretariat,
Ministry of Health, Labour, and Welfare; March 30, 2001.
Alter MJ.
Epidemiology of hepatitis C.
Hepatology 1997;26: (Suppl 1):62S5S.
Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, et al.
Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.
J Clin Microbiol 2000;38:41719.
Yoshida M, Tanemura K, Wakabayashi A, Otsuka Y, Yoshida S,
Onda E, et al.
Study of therapeutic effect of plant complex feed C-UP III on subclinical mastitis caused by S. aureus in dairy cows and activation of blood macrophage (in Japanese with English abstract).
In: Proceedings of Pacific Congress on Milk Quality and Mastitis Control;
2000 Nov 1316, Nagano, Japan; 2000. p. 54752.
Takeishi M, Shimizu S, Tsumagari K, Kinoshita A, Yoshida S,
Momotani E, et al.
Studies on efficacy of the herbal MACH on IgE, interferon and intra-peritoneal macrophage in mice.
In: Proceedings of the Fourth Advanced Traditional Chinese Veterinary Medicine Seminar;
2002 Oct 810, Guangzhou, China.
Chi Institute, Florida, USA; 2002. p. 85102.
Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takekura H,
et al.
Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.
Cancer 2002;94:178795.
Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T,
Ishibashi K, et al.
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.
Nat Med 1998; 4:10657
Return to SHAKLEE STUDIES
Since 12-12-2015
|